HONG KONG — Hong Kong on Wednesday briefly suspended coronavirus illness 2019 (COVID-19) vaccinations utilizing two batches of the therapy developed by Pfizer and BioNTech citing faulty packaging, however the authorities mentioned producers indicated they’d no cause to consider security was in danger, and the transfer was merely a preventative measure.
The federal government mentioned it had acquired discover from Fosun Pharma Industrial (Hong Kong), the distributor of the Pfizer/BioNTech vaccine within the monetary hub and in Macau, that packaging defects had been detected in a vaccine batch—numbered 210102—associated to the closure of bottles.
“BioNTech and Fosun Pharma haven’t discovered any cause to consider that product security is in danger,” the federal government mentioned. It wasn’t instantly clear what number of photographs can be affected, however it mentioned use of batch 210102 can be suspended, as would that of one other batch, numbered 210104, till additional discover.
Fosun Pharma didn’t instantly reply to requests for remark.
On Wednesday, a number of facilities across the Asian monetary hub had been informed by metropolis authorities to cease utilizing the Pfizer/BioNTech vaccine, based on notices seen by residents.
Town started vaccinating residents with doses from China’s Sinovac Biotech Ltd. in February, and commenced providing the Pfizer/BioNTech vaccine in March.
Macau’s Division of Well being mentioned on Wednesday it was suspending manufacturing of the BioNTech vaccine within the neighboring particular administrative area after discovering a packaging flaw. — Farah Grasp/Reuters